Two recent US Food and Drug Administration approvals of lupus nephritis treatments are a positive signal for future drug development in this notoriously challenging disease, Lupus Therapeutics executive director Albert Roy said in a recent interview with Scrip.
Roy has a broad perspective of the field of research. Lupus Therapeutics is an affiliate of the non-profit Lupus Research...